Sun Pharmaceutical Industries announced updated results from the pivotal CK-301-101 trial of UNLOXCYT (cosibelimab-ipdl) for locally advanced cutaneous squamous cell carcinoma (laCSCC) at the ASCO 2026 Annual Meeting. The data, presented on May 31, 2026, in Chicago, demonstrated a 50% objective response rate in 64 patients, with 27% achieving a complete response and 23% a partial response. The median duration of response was not reached over a median follow-up of 31 months, indicating durable clinical efficacy.

The study cohort consisted of patients with a median age of 77 years, 66% of whom were male, reflecting the typical clinical population for this disease. Patients received a median of 29 doses over a median treatment duration of 60 weeks. The safety profile was described as manageable, with treatment-emergent adverse events reported in 95% of patients, though none were fatal. Grade ≥3 treatment-emergent adverse events were reported in 41% of patients and considered treatment-related in 11%.

Efficacy and Safety Data

The investigator-reviewed data highlighted clinically meaningful efficacy alongside a tolerable safety profile. Immune-related adverse reactions were observed in 34% of patients, with Grade ≥3 events occurring in only one patient (2%). The most common adverse events were anemia and diarrhea, each recorded in 27% of patients.

Presentation Details

The poster presentation, titled "Efficacy and safety of cosibelimab 800 mg every 2 weeks for locally advanced cutaneous squamous cell carcinoma: Updated follow-up from a pivotal study," was part of the Melanoma/Skin Cancers session. Dr. Rahul Ladwa, a study co-author, presented the findings. The study represents the second largest prospective study of laCSCC patients treated with PD-(L)1 monotherapy.

UNLOXCYT is indicated for the treatment of adults with metastatic CSCC or laCSCC who are not candidates for curative surgery or curative radiation. The recommended dosage is 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks. The company noted that the 1,200 mg Q3W regimen provides similar overall exposure and PD-L1 receptor coverage as the 800 mg Q2W trial regimen used in the study.

Analyst View: Citi Maintains Buy Rating

Building on the strength of the ASCO 2026 clinical data, Citi has maintained a Buy rating on Sun Pharmaceutical Industries with a target price of ₹2180. The brokerage cited the strong ASCO 2026 data as reinforcing UNLOXCYT's competitive positioning in the laCSCC market, along with improved confidence in the drug's efficacy and tolerability profile. Citi's assessment supports expectations of $400m+ peak sales by FY30 for UNLOXCYT.

Sun Pharmaceutical has stated that it will not provide margin guidance, while flagging that the ongoing West Asia war is expected to affect its performance in future quarters. The company has also noted a visible increase in logistics and shipping costs, adding to the operational headwinds it is currently navigating. These developments come alongside the company's previously shared financial outlook for FY27, which projects top-line growth in the high single digits.

Operational Challenges and Margin Stance

Sun Pharma has explicitly indicated that it will refrain from offering margin guidance, reflecting the uncertainty surrounding its cost structure. The company is noticing an increase in logistics and shipping costs, which could weigh on profitability in the near term. Additionally, the conflict in West Asia is expected to have an impact on the company's performance in future quarters, introducing a geopolitical dimension to its business outlook.

FY27 Financial Guidance Overview

Despite the prevailing challenges, Sun Pharma has shared its financial projections for FY27, covering key parameters including revenue growth expectations, research and development spending, and tax rate estimates. The following table summarizes the key guidance metrics:

R&D Investment and Tax Rate

Sun Pharma has estimated its research and development expenses to be in the range of 6% to 7% of sales, reflecting the company's continued focus on its product pipeline. On the taxation front, the company expects an effective tax rate of 25% for the next year and beyond, providing clarity on its anticipated tax obligations going forward.

Regulatory and Economic Context

The top-line growth guidance of high single digits has been framed within the context of current regulatory and economic conditions, underscoring that the projections are contingent on the prevailing business environment. The additional pressures from the West Asia conflict and rising logistics and shipping costs further underscore the complex operating environment that the company is factoring into its forward planning.